Disc Medicine, Inc. Other Noncash Income (Expense)
Disc Medicine, Inc. (IRON) reported Other Noncash Income (Expense) of $14.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-07-30
- Disc Medicine, Inc. other noncash income (expense) for the quarter ending 2026-06-30 was $2.00K, a 86.67% decline year-over-year.
- Disc Medicine, Inc. other noncash income (expense) for the quarter ending 2026-03-31 was $12.00K.
- Disc Medicine, Inc. other noncash income (expense) for the quarter ending 2025-12-31 was -$1.00K.
- Disc Medicine, Inc. other noncash income (expense) for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Disc Medicine, Inc. other noncash income (expense) for fiscal 2025 was -$1.00K, a 103.70% decline from fiscal 2024.
- Disc Medicine, Inc. other noncash income (expense) for fiscal 2024 was $27.00K.
- Disc Medicine, Inc. other noncash income (expense) for fiscal 2023 was $0.00.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $14.00K 10-Q · filed 2026-07-30 | $13.00K derived: sum of 3 quarters · filed 2026-07-30 | $13.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $12.00K 10-Q · filed 2026-05-05 | $11.00K derived: sum of 2 quarters · filed 2026-05-05 | $11.00K derived: sum of 3 quarters · filed 2026-05-05 | $26.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$1.00K derived: sum of 2 quarters · filed 2026-02-26 | $14.00K derived: sum of 3 quarters · filed 2026-07-30 | -$1.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $15.00K derived: sum of 2 quarters · filed 2026-07-30 | $0.00 10-Q · filed 2025-11-06 | -$15.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $15.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $0.00 10-Q · filed 2026-07-30 | -$15.00K derived: sum of 3 quarters · filed 2026-07-30 | $33.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$15.00K 10-Q · filed 2026-05-05 | -$30.00K derived: sum of 2 quarters · filed 2026-05-05 | $18.00K derived: sum of 3 quarters · filed 2026-05-05 | $12.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $33.00K derived: sum of 2 quarters · filed 2026-02-26 | $27.00K derived: sum of 3 quarters · filed 2026-02-26 | $27.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $48.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $42.00K derived: sum of 2 quarters · filed 2025-11-06 | $42.00K 10-Q · filed 2025-11-06 | $42.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$6.00K 10-Q · filed 2025-08-07 | -$6.00K derived: sum of 3 quarters · filed 2026-02-26 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |